22157.jpg
Global Next Generation Interceptor Industry Research 2024-2034 Featuring Lockheed Martin, Northrop Grumman, RTX, Aerojet Rocketdyne, BAE, Thales, General Dynamics, SAAB, MBDA Konsgberg, Leonardo DRS
May 17, 2024 05:08 ET | Research and Markets
Dublin, May 17, 2024 (GLOBE NEWSWIRE) -- The "Next Generation Interceptor Market - Global and Regional Analysis: Focus on Application, End User, Range, Component, Deployment Method, and Country -...
Red Cross.png
Red Cross announces new field hospital in Rafah
May 16, 2024 10:02 ET | Canadian Red Cross / Croix-Rouge canadienne
OTTAWA, May 16, 2024 (GLOBE NEWSWIRE) --  In response to the overwhelming demand for health care in Gaza, the Canadian Red Cross, in collaboration with the International Committee of the Red Cross...
Moonlake logo.png
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 16, 2024 08:00 ET | MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis...
Muscular Dystrophy Association Advocacy
Muscular Dystrophy Association Celebrates Historic Advancements in Accessible Air Travel as Congress Passes FAA Reauthorization
May 15, 2024 14:57 ET | Muscular Dystrophy Association
Washington, D.C., May 15, 2024 (GLOBE NEWSWIRE) -- Today, the Muscular Dystrophy Association (MDA) celebrates a landmark achievement in accessible air travel as Congress grants final passage to the...
AB Science annonce s
AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2023 et présente un point sur ses activités
May 15, 2024 14:16 ET | AB Science
         COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS ANNUELS AU 31 DECEMBRE 2023 ET LES EVENEMENTS CLEFS DE LA PERIODE Développement clinique Poursuite des...
AB Science reports i
AB Science reports its revenues for the year 2023 and provides an update on its activities
May 15, 2024 14:16 ET | AB Science
         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional...
calian_logo.jpg
Calian annonce des résultats record au deuxième trimestre
May 14, 2024 18:17 ET | Calian Group Ltd.
(Tous les montants dans le communiqué sont en dollars canadiens.) OTTAWA, 14 mai 2024 (GLOBE NEWSWIRE) -- CalianMD Group Ltd. (TSX : CGY), une société de produits et services divers qui...
calian_logo.jpg
Calian Reports Record Results for the Second Quarter
May 14, 2024 18:17 ET | Calian Group Ltd.
Calian® Group Ltd. (TSX:CGY) released its results for the second quarter ended March 31, 2024.
PEGN.jpg
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024 16:02 ET | PepGen Inc.
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – Net...
getimage-48-768x274.png
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 16:05 ET | Capricor Therapeutics
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned...